TRADE COMPANY “HIPOCRATE 2002-SERV”
BUCHAREST – ROMANIA
No. 2065/18.05.2005

Informative report concerning the clinical experiment on embryonic peptides with the Humanofort product.

Humanofort is a natural nutritive supplement, of Romanian origin, obtained from aviary embryos. By an original patented procedure, we obtained an extract from purified standardized embryonic peptides. By administration, per os, to the human beings, especially to the old persons, one obtained benefic effects, both clinically, and as proved by biochemical analyses.

From the beginning, we draw the attention to those who might be concerned that the embryonic peptides contained in the Humanofort should not be confused with the synthetic medicines or with the different food products on the market (eggs powder).

The embryonic peptides are obtained by grinding, molecular screening, purification by preparative chromographic columns using Sephadex, the whole procedure being patented, and subsequently awarded with prizes at the International Show Rooms of Inventions in Brussels and Geneva.

With the limited technical possibilities existing in Romania, the embryonic peptides had been purified and partly studied. So, two bioactive fractions had been isolated, one with the molecular weight (MW) of 5,000 daltons and the other of 10,000 daltons. In vitro, both peptides have the properties stimulating the cell growth and division. In addition, in vivo, we observed a significant decreasing of the oxidative stress, and an adjustment of the patients’ lipid metabolism.

THE SCOPE OF OUR RESEARCH is to demonstrate that the embryo-therapy can be up-dated by means of modern techniques. The scientific researches performed during the last years demonstrated the stimulating effect of the stem cells and embryo growth factors, as regulators of metabolic processes in organism, or as pre-hormones – inducers of the adjustment.

Humanofort was homologated in Romania as a nutritive supplement. Humanofort was also registered with the FDA (The Food and Drug Administration) being distributed 24 years ago on the American market. No claims received during this period from the consumers’ part.

Although some American scientists and businessmen expressed their skepticism, however Dr. Eric Serrano from Pickerington Laboratory – Ohio, checked clinically the embryonic peptides effect from the Humanofort, and discovered surprising properties.

We applied Dr. Serrano’s protocol, as rigorously as possible, on a double number of subjects, the results being contained in this report.
In the interpretation of the results obtained by us, we considered that a statistic computation is not required, as used in case of pharmacologic-clinic studies (probability, X2, a.s.o.) because each subject has been its own witness. A number of 20 biochemical and immunological parameters before and after the treatment with the Humanofort had been performed with each subject. In addition, as you can see in the tables here enclosed, in case of several parameters, the variations after treatment had been significant and grouped toward the benefic effects of normalization within the physiological limits.

The subjects had been selected by randomizing, according to the age (over 50 years old), and the increased initial value of total cholesterol. The sample of subjects is of course reduced enough, but the study could be extended to a greater number of persons corresponding to a numerous population.

The lot of 40 subjects over 50 years old comprised volunteers, 18 men and 22 women, selected from family doctors’ files in Bucharest.

The results had been so edifying for the most part of studied parameters. The modifications that took place in the lipid metabolism draw especially our attention, being well known that the older persons have frequent dislipidemies. We studied also the endocrine modifications, and the growth factors, frequently modified to the aged persons. As we showed in the general catalogue, we performed clinical preliminary studies on human beings for control, demonstration of the lack of toxicity and Placebo’s effect.

Working manner
As we mentioned above, one took over previously blood samples from the persons involved in this study, after that they received the Humanofort product for two months of ambulatory treatment. After this period, one took over again blood and urine samples. Each person used four (4) capsules per day, two in the morning, and two in the evening, receiving 200 mg active embryonic peptides per day. The biologic samples had been processed with the European MedicCover Rombel Laboratory, having an ISO international license.

The results obtained are associated to this report, both for each person involved, and as their general interpretation.

  1. The first interpretation performed on 40 subjects belongs to Dr. Radu Olinescu.
  2. The second one, performed on a number of 14 subjects from 40 subjects, belongs to Dr. Florin Oancea, but these results are the most significant because they had been medically supervised rigorously, in a stationary hospital.

GENERAL THEORETIC CONCLUSIONS

  1. The embryonic peptides can be considered as pre-hormones or inducers in the first stages of life evolution, having as role the adjustment of the essential metabolic processes, especially the lipid, endocrine ones. On the phylogenetic line, the embryonic peptides belong to the growth factors existent to all superior mammals. In this sense, we performed comparative studies of embryonic peptides extracted from several species of superior mammals.
  2. The embryonic peptides had been studied physiologically by radioactive marker techniques (markers with Iodine125 and H3). So, it was proved that the embryonic peptides penetrate through the membranes – intestinal barrier in blood, in contradiction with some ancient opinions, in compliance with which only the amino acids can cross this barrier.
  3. The embryonic peptides pass directly from the intestine in blood, being taken over in the sanguine circulation. Humanofort is delivered as capsules that allow the crossing of the stomach, and the dissolution at the intestinal pH level.

The embryonic peptides destiny could be different. Some of them could be indifferent for the cell receivers, and will be eliminated by renal way (having the molecular weight reduced).

Other embryonic peptides could be attracted toward receivers with affinity from the cell membrane, where could be taken over in triggering some intra-cell adjustment mechanisms (feed-back, or feed-before type) modifying some phases in the synthesis, or the effect of some hormones by homeostasis mechanisms.

After all probabilities, the embryonic peptides act similarly to the IGF (Insulin-like Growth Factor), as one can observe by the results obtained on the insulin, lipid levels, or even of the IGF from the investigated subjects’ blood. So, we can correlate it with the diminishing of hyper-insulinism (frequent in the USA) and the proliferative aggression.

Within our new stage of research already started, we will approach the possible IGF regulating effect, to the growth hormone by means of the embryonic peptides, with the hope of the benefic modification of the Carcino Embryonic Antigen (CEA), and the Prostatec Specific Antigen (PSA) markers, as well as of the dependent treatments.

Yours sincerely,
The authors: Dr. Gh. Mihãescu
Dr. Radu Olinescu
Dr. Florin Oancea